NCT05376865

Brief Summary

46 eligible overweight women with hypovitaminosis D are assigned to either vitamin D or control group using block randomization method. Vitamin D3 pearl (Zahravi Pharma Co, Tabriz, Iran) containing 50000 IU cholecalciferol or placebo are administered weekly for 12 weeks. Participants in both groups are structured to hold their sun exposure and physical activity habits and not take any vitamin supplements during the study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 29, 2021

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 29, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2022

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 11, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 17, 2022

Completed
Last Updated

May 17, 2022

Status Verified

May 1, 2022

Enrollment Period

3 months

First QC Date

May 11, 2022

Last Update Submit

May 11, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Serum 25(OH)D

    Fasting serum 25-hydroxyvitamin D level

    12 weeks

  • Weight

    Subject's weight wearing light clothing

    12 weeks

Secondary Outcomes (9)

  • Waist circumference

    12 weeks

  • Fat mass

    12 weeks

  • Serum Fasting Glucose

    12 weeks

  • Serum total cholesterol

    12 weeks

  • Serum triglyceride

    12 weeks

  • +4 more secondary outcomes

Study Arms (2)

Intervention

EXPERIMENTAL

Vitamin D3 supplement every week

Dietary Supplement: Vitamin D supplement

Control

PLACEBO COMPARATOR

Placebo every week

Dietary Supplement: Vitamin D supplement

Interventions

Vitamin D supplementDIETARY_SUPPLEMENT

The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.

ControlIntervention

Eligibility Criteria

Age20 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • low serum vitamin D level \<30ng/ml
  • \<BMI\<30 kg/m2
  • Age: 20-50
  • Free of chronic diseased such as cancer, diabetes, cardiovascular disease, renal diseases, gastrointestinal diseases, no multivitamin supplement intake, no change in weight in the last 3 months

You may not qualify if:

  • Getting pregnant during the study
  • Suffering from thyroid disorders and other diseases mentioned during the study
  • Not taking supplements weekly

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute (NNFTRI) and Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Tehran, Iran

Location

MeSH Terms

Conditions

OverweightVitamin D Deficiency

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsAvitaminosisDeficiency DiseasesMalnutrition

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Prof.

Study Record Dates

First Submitted

May 11, 2022

First Posted

May 17, 2022

Study Start

September 29, 2021

Primary Completion

December 29, 2021

Study Completion

February 20, 2022

Last Updated

May 17, 2022

Record last verified: 2022-05

Locations